VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

LLM 2021 | Updates on the treatment of MDS

Sangmin Lee, MD, Weill Cornell Medicine, New York, NY, outlines new treatments for high-risk myelodysplastic syndromes (MDS). The current standard of care includes hypomethylating agents and recent advancements include oral decitabine and cedazuridine, which represent a convenient option for patients. Venetoclax, which has been approved in acute myeloid leukemia (AML) and hypomethylating agents, as well as cemiplimab or magrolimab with azacytidine, are additional promising treatment regimens in patients with high-risk MDS. This interview took place at the Lymphoma, Leukemia & Myeloma Congress 2021.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter